BETA
Your AI-Trained Oncology Knowledge Connection!
Following a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
FDA Approves Taletrectinib in ROS1+ NSCLC
Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.
Adopting Best Practices for Administering TROP2-Directed ADCs in NSCLC
Experts from Washington University in St. Louis discuss dosing considerations and toxicity management strategies for TROP2-targeted ADCs in NSCLC.
Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.
Improving NSCLC Surgery Recovery After Climate Disaster Exposure
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
An International Search for Lung Cancer Treatment Leads to Double Lung Transplant
The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.
Rechallenge With RET Inhibitors Shows Efficacy in Pretreated NSCLC
RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.